Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

256 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evidence for G-quadruplex in the promoter of vegfr-2 and its targeting to inhibit tumor angiogenesis.
Salvati E, Zizza P, Rizzo A, Iachettini S, Cingolani C, D'Angelo C, Porru M, Randazzo A, Pagano B, Novellino E, Pisanu ME, Stoppacciaro A, Spinella F, Bagnato A, Gilson E, Leonetti C, Biroccio A. Salvati E, et al. Among authors: gilson e. Nucleic Acids Res. 2014 Mar;42(5):2945-57. doi: 10.1093/nar/gkt1289. Epub 2013 Dec 11. Nucleic Acids Res. 2014. PMID: 24335081 Free PMC article.
Telomere damage induced by the G-quadruplex ligand RHPS4 has an antitumor effect.
Salvati E, Leonetti C, Rizzo A, Scarsella M, Mottolese M, Galati R, Sperduti I, Stevens MF, D'Incalci M, Blasco M, Chiorino G, Bauwens S, Horard B, Gilson E, Stoppacciaro A, Zupi G, Biroccio A. Salvati E, et al. Among authors: gilson e. J Clin Invest. 2007 Nov;117(11):3236-47. doi: 10.1172/JCI32461. J Clin Invest. 2007. PMID: 17932567 Free PMC article.
G-quadruplex ligand RHPS4 potentiates the antitumor activity of camptothecins in preclinical models of solid tumors.
Leonetti C, Scarsella M, Riggio G, Rizzo A, Salvati E, D'Incalci M, Staszewsky L, Frapolli R, Stevens MF, Stoppacciaro A, Mottolese M, Antoniani B, Gilson E, Zupi G, Biroccio A. Leonetti C, et al. Among authors: gilson e. Clin Cancer Res. 2008 Nov 15;14(22):7284-91. doi: 10.1158/1078-0432.CCR-08-0941. Clin Cancer Res. 2008. PMID: 19010844
DNA damage persistence as determinant of tumor sensitivity to the combination of Topo I inhibitors and telomere-targeting agents.
Biroccio A, Porru M, Rizzo A, Salvati E, D'Angelo C, Orlandi A, Passeri D, Franceschin M, Stevens MF, Gilson E, Beretta G, Zupi G, Pisano C, Zunino F, Leonetti C. Biroccio A, et al. Among authors: gilson e. Clin Cancer Res. 2011 Apr 15;17(8):2227-36. doi: 10.1158/1078-0432.CCR-10-3033. Epub 2011 Feb 25. Clin Cancer Res. 2011. PMID: 21355072
TRF2 inhibits a cell-extrinsic pathway through which natural killer cells eliminate cancer cells.
Biroccio A, Cherfils-Vicini J, Augereau A, Pinte S, Bauwens S, Ye J, Simonet T, Horard B, Jamet K, Cervera L, Mendez-Bermudez A, Poncet D, Grataroli R, de Rodenbeeke CT, Salvati E, Rizzo A, Zizza P, Ricoul M, Cognet C, Kuilman T, Duret H, Lépinasse F, Marvel J, Verhoeyen E, Cosset FL, Peeper D, Smyth MJ, Londoño-Vallejo A, Sabatier L, Picco V, Pages G, Scoazec JY, Stoppacciaro A, Leonetti C, Vivier E, Gilson E. Biroccio A, et al. Among authors: gilson e. Nat Cell Biol. 2013 Jul;15(7):818-28. doi: 10.1038/ncb2774. Epub 2013 Jun 23. Nat Cell Biol. 2013. PMID: 23792691
Shading the TRF2 recruiting function: a new horizon in drug development.
Di Maro S, Zizza P, Salvati E, De Luca V, Capasso C, Fotticchia I, Pagano B, Marinelli L, Gilson E, Novellino E, Cosconati S, Biroccio A. Di Maro S, et al. Among authors: gilson e. J Am Chem Soc. 2014 Dec 3;136(48):16708-11. doi: 10.1021/ja5080773. Epub 2014 Nov 19. J Am Chem Soc. 2014. PMID: 25393214
256 results